Clinical Trial Update: Indirect Comparison Between Eltrombopag & Romiplostim

View source ↗

Summary

This completed clinical trial update presents an indirect comparison of eltrombopag and romiplostim for thrombocytopenia to assess relative efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)
• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Thrombocytopaenia | Status: COMPLETED